We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 1.10 | 1.40 | 1.25 | 1.25 | 1.25 | 592,472 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.57 | 1.69M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/5/2018 13:49 | Dave....just for cancer? The disease that one in two of us WILL experience in our lifetimes......that' | coldspring | |
21/5/2018 13:39 | Because the government wants to use ai for ALL ILLNESSES, and all pyc does is model dosage predictions for trials, just for cancer drugs. Hence why they will need to use companies that cover as many bases as possible, like Oxford Bio, based in OXFORD, as you just mention, who have a plethora of advanced simulation systems for many drugs and diseases, actually modelling for the design, not just for mere dosing. | davevt | |
21/5/2018 13:29 | It's incredible, the Government has come out with a MASSIVE Industrial Strategy initiative to invest in jobs and tech in this Country in Precision Medicine and AI which is pretty much solely focused around Oxford (i.e. PYC) and nobody seems to have picked up on it! Here are the clues for the hard of thinking :- PYC have been talking about Precision Medicine, Big Data, Cloud and AI PYC have now had multiple contracts from the Government for Precision Medicine focused on Cancer treatments PYC are currently pitching for more contracts with the Government in Precision Medicine/AI arena PYC are working with Government/Oxford Uni/Cancer Research UK/Oxford NHS etc on a CANCER DSS tool to help improve cancer treatments PYC is the future and you can buy the Company right now for £3m when its peers are valued at hundreds of millions and billions ! | the stigologist | |
21/5/2018 11:31 | And with a ridiculous liw valuation!!! | billthebank | |
21/5/2018 11:23 | Agreed, could be a great link? How many companies available to buy stock in that are in this area? ;) | margic | |
21/5/2018 10:07 | Stig, it says treatable illnesses, not cancer, so once again why would you think pyc would get a look in when they only do dosage modelling for drug trials for cancer drugs, and all the other big companies you keep mentioning like OXFORD biometrics do a.i design for loads of drugs for loads of ILLNESSES.? | davevt | |
21/5/2018 09:41 | Physiomics KLAXON Physiomics KLAXON !!!! The Prime Minister is expected to say: Late diagnosis of otherwise treatable illnesses is one of the biggest causes of avoidable deaths. And the development of smart technologies to analyse great quantities of data quickly and with a higher degree of accuracy than is possible by human beings opens up a whole new field of medical research and gives us a new weapon in our armoury in the fight against disease. Achieving this mission will not only save thousands of lives. It will incubate a whole new industry around AI-in-healthcare, creating high-skilled science jobs across the country, drawing on existing centres of excellence in places like Edinburgh, Oxford and Leeds – and helping to grow new ones. | the stigologist | |
21/5/2018 09:38 | there is some big news coming our way folks Physiomics doing their marketing roadshow Government talking about funding for data and AI We are waiting for at least one funding round from Govt but I expect more on top | the stigologist | |
21/5/2018 08:53 | Uh oh, Stig is trying to ramp like hell again. If ai for cancer is the next big thing, why do you think they would bother with pyc who only do dosage modelling and not go straight to all the Mega behemoth ai companies YOU KEEP MENTIONING in your posts that are the leaders in their field and worth tens to hundreds of millions. Give one reason why pyc would even get a look in? | davevt | |
21/5/2018 06:23 | BBC the FT the Times Theresa May the Prime Minister saying AI to deal with Cancer Massive massive news and contracts coming for PYC I bet | the stigologist | |
21/5/2018 06:22 | It's everywhere!!! | the stigologist | |
20/5/2018 22:22 | Just got to look at any basic 3month chart as a novice or pro. The move out to one year for first target highs. Thinking a good run starts this week onwards, I reckon it will be quick and with any luck harsh, stock building profit taking opportunity araising imo. A bit of news momentum would be nice, I'm more hoping on volume and price movement to kick off. That's what will trigger value for all here. Time to start warming up. | margic | |
20/5/2018 08:40 | 6p is not the new 1p. 6p is the residual left from the 32p it soared to last November. Conscious of the inevitable drop back to 2p they release news whenever they can no matter how vacuous. In the old days they would have been too ashamed to release news detailing a £48k contract. But today to prop up a worthless AIM stock investors need news, news and more news. | pwhite73 | |
19/5/2018 11:56 | 6p is the new 1p News from this base should see the rise to 50-100p where this belongs | the stigologist | |
19/5/2018 11:54 | Shareholder base seems to be improving | the stigologist | |
17/5/2018 12:30 | 500k contract RnS??? | spacedust | |
16/5/2018 09:13 | Calm before the storm here. Let's see what the company says when they release their results | billthebank | |
16/5/2018 08:30 | 5m is a lot when pyc charge 35k per drug modelling service. Basically what you're hoping for is some brand new pharma is gonna pop up with 150 cancer drugs to test lol. Never gonna happen. They might have one or two drugs a year, or if they've already been a customer for years, progressed onto clinical trials which commands a bit more money. But you can't quote pie in the sky figures that don't add up to the services charged. | davevt |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions